

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**KEESE, JAMES P.**

2. Address:

400 NORTH CAPITOL STREET NW SUITE 585, WASHINGTON, DC 20001

3. Principal place of business (if different from line 2):

4. Contact Name: KELLY MAUGHAN

Telephone: 2026241465

E-mail (optional): kmaughan@holcherickson.com

Senate ID #: 74556-12

House ID #: 36042000

7. Client Name: ☐ Self

**TEVA PHARMACEUTICALS USA**

### TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 80,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only  
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: KEESE, JAMES P. Client Name: TEVA PHARMACEUTICALS USA

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

President Bush FY 2008 Budget Request - \$15.7 million dollars Generic Drug User Fees Matters relating to FDA Office of Generic Drugs funding

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Registrant Name: KEESE, JAMES P. Client Name: TEVA PHARMACEUTICALS USA

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 1432, Preserve Access to Affordable Generics Act, S. 316, Preserve Access to Affordable Generics Act, H.R. 1908, Patent Reform Act of 2007, S. 1145 Patent Reform Act of 2007, H.R. 1902 Protecting Consumer Access to Generic Drugs Act

17. House(s) of Congress and Federal agencies contacted:

Federal Trade Commission (FTC)  
HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R.976 Children's Health Insurance Program Reauthorization Act of 2007 S.1893 Children's Health Insurance Program Reauthorization Act of 2007 H.R.3162 Children's Health and Medicare Protection Act of 2007 S. 1951 The Fair Medicaid Drug Payment Act of 2007

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

S. 25 Citizen Petition Fairness and Accuracy Act of 2007, S.623/HR 1038 Access to Life-Saving Medicine Act, S. 438/HR 806 Fair Prescription Drug Competition Act, S.1082 Food and Drug Administration Revitalization Act, S. 1088 Lower PRICED Drugs Act, S.1505 Affordable Biologics for Consumers Act, S. 1695 Biologics Price Competition and Innovation Act of 2007, H.R. 1956, H.R. 2900, H.R. 3140, H.R. 2606, HR 3580, HR 3610

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Registrant Name: KEESE, JAMES P. Client Name: TEVA PHARMACEUTICALS USA

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Matters relating to Israeli data exclusivity. Matters relating to pharmaceutical provisions in free trade agreements.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEESE, JAMES

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: KELLY MAUGHAN, BUSINESS REPRES -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Feb 14, 2008

Printed Name and Title: -